Suchergebnisse - "Kiguba, Ronald"

PubPharm (72)

1

Epidemiology of adverse drug reactions to antihypertensive, antithrombotic and antidiabetic medications among adult inpatients at a National Referral Hospital, Uganda

enthalten in: Expert opinion on drug safety | 2024

von Kuteesa, J. | Nasasira, M. | Kiguba, R.

2

Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda : burden and determinants

enthalten in: BMC infectious diseases | 2024

von Kigongo, V. | Nankabirwa, J. | Kitutu, F. | +6

3

Dyslipidemia among adult people living with HIV on dolutegravir – based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants

enthalten in: BMC infectious diseases | 2024

von Kigongo, V. | Nankabirwa, J. | Kitutu, F. | +6

4

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

enthalten in: ResearchSquare.com | 2023

von Mulindwa, F. | Castelnuovo, B. | Brusselaers, N. | +5

5

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

enthalten in: AIDS research and therapy | 2023

von Mulindwa, F. | Castelnuovo, B. | Brusselaers, N. | +6

UpdateOf: Res Sq. 2023 Jul 20;:. - PMID 37502917

6

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

enthalten in: AIDS research and therapy | 2023

von Mulindwa, F. | Castelnuovo, B. | Brusselaers, N. | +6

7

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

enthalten in: AIDS research and therapy | 2023

von Mulindwa, F. | Castelnuovo, B. | Brusselaers, N. | +6

8

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks

enthalten in: Research square | 2023

von Mulindwa, F. | Schwarz, J. | Brusselaers, N. | +8

9

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

enthalten in: Research square | 2023

von Mulindwa, F. | Castelnuovo, B. | Brusselaers, N. | +5

UpdateIn: AIDS Res Ther. 2023 Sep 9;20(1):65. - PMID 37689695

10

Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda : A Qualitative Study

enthalten in: Drug safety | 2023

von Kiguba, R. | Zakumumpa, H. | Ndagije, H. | +5

1
2
3
4
5
6
7
8
Nächster »
[8]